Pharmacogenetics of Disulfiram for Cocaine

PHASE2CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Cocaine DependenceOpioid Dependence
Interventions
DRUG

Disulfiram

Disulfiram 250 mg/day by mouth daily during study weeks 2-13. Disulfiram discontinued during study weeks 14-15.

DRUG

Methadone

Initial dose 25 mg; increased by 5 mg at each subsequent daily dosing until 60 mg maintenace dose reached.

BEHAVIORAL

CBT

1-hour weekly, individual, manual-guided Cognitive Behaviorial Therapy.

OTHER

Lactose

Lactose was added to both the active disulfiram and placebo doses so they tasted identical.

Trial Locations (1)

77030

Michael E. DeBakey VA Medical Center, Houston

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

collaborator

Yale University

OTHER

lead

Baylor College of Medicine

OTHER

NCT00149630 - Pharmacogenetics of Disulfiram for Cocaine | Biotech Hunter | Biotech Hunter